- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06357533
Fas III, öppen märkning, studie av första linjens Dato-DXd i kombination med Rilvegostomig för avancerad icke-skivepitelcancer NSCLC med högt PD-L1-uttryck (TC ≥ 50%) och utan genomförbara genomiska förändringar (TROPION-Lung10)
En fas III, randomiserad, öppen, global studie av datopotamab deruxtecan (Dato-DXd) i kombination med rilvegostomig eller rilvegostomig monoterapi kontra pembrolizumab monoterapi för första linjens behandling av deltagare med lokalt avancerad eller metastaserad icke-LCSquam PD-L1-uttryck (TC ≥ 50%) och utan genomförbara genomiska förändringar (TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
-
Birtinya, Australien, 4575
- Indragen
- Research Site
-
Blacktown, Australien, 2148
- Indragen
- Research Site
-
Clayton, Australien, 3168
- Rekrytering
- Research Site
-
Gosford, Australien, 2250
- Rekrytering
- Research Site
-
Melbourne, Australien, 3000
- Indragen
- Research Site
-
South Brisbane, Australien, QL 4101
- Rekrytering
- Research Site
-
Wodonga, Australien, 3690
- Rekrytering
- Research Site
-
-
-
-
-
Anderlecht, Belgien, 1070
- Indragen
- Research Site
-
Bruges, Belgien, 8000
- Rekrytering
- Research Site
-
Hasselt, Belgien, 3500
- Rekrytering
- Research Site
-
La Louvière, Belgien, 7100
- Rekrytering
- Research Site
-
Liège, Belgien, 4000
- Rekrytering
- Research Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Rekrytering
- Research Site
-
Curitiba, Brasilien, 80730-150
- Rekrytering
- Research Site
-
Florianópolis, Brasilien, 88034-000
- Rekrytering
- Research Site
-
Ipatinga, Brasilien, 35162-189
- Rekrytering
- Research Site
-
Natal, Brasilien, 59075-740
- Rekrytering
- Research Site
-
Porto Alegre, Brasilien, 91350-200
- Rekrytering
- Research Site
-
Rio de Janeiro, Brasilien, 22211-230
- Rekrytering
- Research Site
-
Santa Maria, Brasilien, 97015-450
- Rekrytering
- Research Site
-
São Paulo, Brasilien, 01221-020
- Rekrytering
- Research Site
-
Taubaté, Brasilien, 12030-200
- Rekrytering
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 99508
- Rekrytering
- Research Site
-
-
Arizona
-
Tucson, Arizona, Förenta staterna, 85719
- Rekrytering
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- Rekrytering
- Research Site
-
Springdale, Arkansas, Förenta staterna, 72762
- Rekrytering
- Research Site
-
-
California
-
Anaheim, California, Förenta staterna, 92801
- Rekrytering
- Research Site
-
Beverly Hills, California, Förenta staterna, 90211
- Rekrytering
- Research Site
-
Fountain Valley, California, Förenta staterna, 92708
- Rekrytering
- Research Site
-
Newport Beach, California, Förenta staterna, 92663
- Upphängd
- Research Site
-
-
Florida
-
Clermont, Florida, Förenta staterna, 34711
- Rekrytering
- Research Site
-
Gainesville, Florida, Förenta staterna, 32608
- Rekrytering
- Research Site
-
Miami Beach, Florida, Förenta staterna, 33140
- Rekrytering
- Research Site
-
Orange City, Florida, Förenta staterna, 32763
- Rekrytering
- Research Site
-
Orlando, Florida, Förenta staterna, 32806
- Rekrytering
- Research Site
-
Orlando, Florida, Förenta staterna, 32827
- Indragen
- Research Site
-
West Palm Beach, Florida, Förenta staterna, 33401
- Rekrytering
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Rekrytering
- Research Site
-
Atlanta, Georgia, Förenta staterna, 30318
- Rekrytering
- Research Site
-
Atlanta, Georgia, Förenta staterna, 30342
- Indragen
- Research Site
-
Atlanta, Georgia, Förenta staterna, 30303
- Upphängd
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, Förenta staterna, 60521
- Rekrytering
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Förenta staterna, 46062
- Rekrytering
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, Förenta staterna, 42003
- Rekrytering
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Förenta staterna, 21401
- Rekrytering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Research Site
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Research Site
-
-
Michigan
-
Dearborn, Michigan, Förenta staterna, 48126
- Rekrytering
- Research Site
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Rekrytering
- Research Site
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Rekrytering
- Research Site
-
Traverse City, Michigan, Förenta staterna, 49684
- Indragen
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Förenta staterna, 39401
- Rekrytering
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64132
- Rekrytering
- Research Site
-
-
Montana
-
Bozeman, Montana, Förenta staterna, 59715
- Indragen
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, Förenta staterna, 68803
- Rekrytering
- Research Site
-
Omaha, Nebraska, Förenta staterna, 68130
- Rekrytering
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89102
- Rekrytering
- Research Site
-
Reno, Nevada, Förenta staterna, 89502
- Indragen
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, Förenta staterna, 08043
- Upphängd
- Research Site
-
-
New York
-
Stony Brook, New York, Förenta staterna, 11794
- Rekrytering
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, Förenta staterna, 27834
- Rekrytering
- Research Site
-
Salisbury, North Carolina, Förenta staterna, 28144
- Rekrytering
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- Rekrytering
- Research Site
-
Columbus, Ohio, Förenta staterna, 43210
- Indragen
- Research Site
-
Maumee, Ohio, Förenta staterna, 43537
- Rekrytering
- Research Site
-
Toledo, Ohio, Förenta staterna, 43623
- Rekrytering
- Research Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- Indragen
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Förenta staterna, 29607
- Rekrytering
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Rekrytering
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Förenta staterna, 37404
- Indragen
- Research Site
-
Knoxville, Tennessee, Förenta staterna, 37920
- Indragen
- Research Site
-
-
Texas
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Indragen
- Research Site
-
Houston, Texas, Förenta staterna, 77090
- Upphängd
- Research Site
-
Kingwood, Texas, Förenta staterna, 77339
- Rekrytering
- Research Site
-
Odessa, Texas, Förenta staterna, 79761
- Rekrytering
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, Förenta staterna, 22060
- Rekrytering
- Research Site
-
Leesburg, Virginia, Förenta staterna, 20176
- Rekrytering
- Research Site
-
Midlothian, Virginia, Förenta staterna, 23114
- Rekrytering
- Research Site
-
Richmond, Virginia, Förenta staterna, 23230
- Rekrytering
- Research Site
-
-
Washington
-
Tacoma, Washington, Förenta staterna, 98405
- Rekrytering
- Research Site
-
Vancouver, Washington, Förenta staterna, 98684
- Rekrytering
- Research Site
-
Wenatchee, Washington, Förenta staterna, 98801
- Rekrytering
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, Förenta staterna, 54911
- Rekrytering
- Research Site
-
-
-
-
-
Chennai, Indien, 600031
- Rekrytering
- Research Site
-
Dwārka, Indien, 110075
- Rekrytering
- Research Site
-
Jaipur, Indien, 302004
- Rekrytering
- Research Site
-
Kolkata, Indien, 700099
- Rekrytering
- Research Site
-
Marg Jaipur, Indien, 302004
- Indragen
- Research Site
-
Nagpur, Indien, 440001
- Rekrytering
- Research Site
-
Nashik, Indien, 422011
- Rekrytering
- Research Site
-
New Delhi, Indien, 11029
- Rekrytering
- Research Site
-
New Delhi, Indien, 110085
- Rekrytering
- Research Site
-
Surat, Indien, 395002
- Rekrytering
- Research Site
-
Thiruvananthapuram, Indien, 695011
- Indragen
- Research Site
-
-
-
-
-
Bergamo, Italien, 24125
- Rekrytering
- Research Site
-
Genoa, Italien, 16132
- Rekrytering
- Research Site
-
Milan, Italien, 20141
- Rekrytering
- Research Site
-
Milan, Italien, 20162
- Rekrytering
- Research Site
-
Monza, Italien, 20052
- Rekrytering
- Research Site
-
Padova, Italien, 35128
- Rekrytering
- Research Site
-
Pavia, Italien, 27100
- Rekrytering
- Research Site
-
Ravenna, Italien, 48100
- Rekrytering
- Research Site
-
Roma, Italien, 00128
- Rekrytering
- Research Site
-
Rozzano, Italien, 20089
- Rekrytering
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8431
- Rekrytering
- Research Site
-
Bunkyō City, Japan, 160-0023
- Rekrytering
- Research Site
-
Fukuoka, Japan, 812-8582
- Rekrytering
- Research Site
-
Fukuoka, Japan, 814-0180
- Rekrytering
- Research Site
-
Hakodate-shi, Japan, 040-8611
- Rekrytering
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Rekrytering
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Rekrytering
- Research Site
-
Hirosaki-shi, Japan, 036-8563
- Rekrytering
- Research Site
-
Hiroshima, Japan, 730-8518
- Rekrytering
- Research Site
-
Kanazawa, Japan, 920-8641
- Rekrytering
- Research Site
-
Kashiwa, Japan, 227-8577
- Rekrytering
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Rekrytering
- Research Site
-
Kumamoto, Japan, 860-8556
- Rekrytering
- Research Site
-
Matsusaka-shi, Japan, 515-8544
- Rekrytering
- Research Site
-
Matsuyama, Japan, 790-0024
- Rekrytering
- Research Site
-
Nagoya, Japan, 460-0001
- Rekrytering
- Research Site
-
Niigata, Japan, 951-8566
- Rekrytering
- Research Site
-
Okayama, Japan, 700-8558
- Rekrytering
- Research Site
-
Osaka, Japan, 545-8586
- Indragen
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Rekrytering
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Rekrytering
- Research Site
-
Sapporo, Japan, 003-0804
- Rekrytering
- Research Site
-
Takaoka-shi, Japan, 933-8555
- Rekrytering
- Research Site
-
Takatsuki-shi, Japan, 569-8686
- Rekrytering
- Research Site
-
Tokushima, Japan, 770-8503
- Rekrytering
- Research Site
-
Tokyo, Japan, 104-0045
- Rekrytering
- Research Site
-
Utsunomiya, Japan, 320-0834
- Rekrytering
- Research Site
-
Yokohama, Japan, 221-0855
- Rekrytering
- Research Site
-
-
-
-
-
Chicoutimi, Kanada, G7H 5H6
- Rekrytering
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, VSZ 4E6
- Rekrytering
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Indragen
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Rekrytering
- Research Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 4L6
- Rekrytering
- Research Site
-
Newmarket, Ontario, Kanada, L3Y 2P9
- Indragen
- Research Site
-
Oshawa, Ontario, Kanada, L1G 2B9
- Rekrytering
- Research Site
-
Toronto, Ontario, Kanada, M4N 3M5
- Indragen
- Research Site
-
-
Quebec
-
Lévis, Quebec, Kanada, G6V 0B8
- Rekrytering
- Research Site
-
Montreal, Quebec, Kanada, H4J 1C5
- Rekrytering
- Research Site
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrytering
- Research Site
-
Montreal, Quebec, Kanada, H3T 1M5
- Indragen
- Research Site
-
Rimouski, Quebec, Kanada, G5L 5T1
- Rekrytering
- Research Site
-
Trois-Rivières, Quebec, Kanada, G8Z 3R9
- Rekrytering
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 4H4
- Rekrytering
- Research Site
-
-
-
-
-
Beijing, Kina, 100142
- Rekrytering
- Research Site
-
Beijing, Kina, 101149
- Rekrytering
- Research Site
-
Changchun, Kina, 130000
- Rekrytering
- Research Site
-
Changsha, Kina, 410013
- Rekrytering
- Research Site
-
Chengdu, Kina, 610000
- Rekrytering
- Research Site
-
Chengdu, Kina, 610041
- Rekrytering
- Research Site
-
Chongqing, Kina, 400030
- Rekrytering
- Research Site
-
Fuzhou, Kina, 350014
- Rekrytering
- Research Site
-
Guangzhou, Kina, 510080
- Rekrytering
- Research Site
-
Hangzhou, Kina, 310006
- Rekrytering
- Research Site
-
Hangzhou, Kina, 310022
- Rekrytering
- Research Site
-
Hangzhou, Kina, 310016
- Rekrytering
- Research Site
-
Harbin, Kina, 150049
- Rekrytering
- Research Site
-
Hefei, Kina, 230601
- Rekrytering
- Research Site
-
Hefei, Kina, 230031
- Indragen
- Research Site
-
Jinan, Kina, 250117
- Rekrytering
- Research Site
-
Jining, Kina, 272011
- Indragen
- Research Site
-
Kunming, Kina, 650118
- Rekrytering
- Research Site
-
Lanzhou, Kina, 730000
- Rekrytering
- Research Site
-
Linhai, Kina, 317000
- Rekrytering
- Research Site
-
Linyi, Kina, 276001
- Rekrytering
- Research Site
-
Nanjing, Kina, 210009
- Rekrytering
- Research Site
-
Nanning, Kina, 530021
- Rekrytering
- Research Site
-
Nanning, Kina, 530000
- Rekrytering
- Research Site
-
Shanghai, Kina, 200032
- Rekrytering
- Research Site
-
Shanghai, Kina, 200030
- Rekrytering
- Research Site
-
Shanghai, Kina, 200433
- Rekrytering
- Research Site
-
Shenyang, Kina, 110022
- Rekrytering
- Research Site
-
Taiyuan, Kina, 030000
- Rekrytering
- Research Site
-
Tianjin, Kina, 300060
- Rekrytering
- Research Site
-
Wenzhou, Kina, 325000
- Rekrytering
- Research Site
-
Wuhan, Kina, 430022
- Rekrytering
- Research Site
-
Wuhan, Kina, 430030
- Rekrytering
- Research Site
-
Wuhan, Kina, 430010
- Rekrytering
- Research Site
-
Wuhan, Kina, 430000
- Rekrytering
- Research Site
-
Xi'an, Kina, 710061
- Rekrytering
- Research Site
-
Yangzhou, Kina, 225001
- Rekrytering
- Research Site
-
Zhengzhou, Kina, 450000
- Rekrytering
- Research Site
-
Zhengzhou, Kina, 450008
- Rekrytering
- Research Site
-
-
-
-
-
Olsztyn, Polen, 10-357
- Rekrytering
- Research Site
-
Poznan, Polen, 60-569
- Rekrytering
- Research Site
-
Przemyśl, Polen, 37-700
- Rekrytering
- Research Site
-
Warsaw, Polen, 02-781
- Rekrytering
- Research Site
-
Warsaw, Polen, 01-138
- Rekrytering
- Research Site
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Rekrytering
- Research Site
-
-
-
-
-
Alicante, Spanien, 03010
- Rekrytering
- Research Site
-
Barcelona, Spanien, 08036
- Rekrytering
- Research Site
-
Barcelona, Spanien, 08003
- Rekrytering
- Research Site
-
Barcelona, Spanien, 08041
- Har inte rekryterat ännu
- Research Site
-
Jerez de la Frontera, Spanien, 11407
- Rekrytering
- Research Site
-
Reus, Spanien, 43204
- Rekrytering
- Research Site
-
Salamanca, Spanien, 37007
- Indragen
- Research Site
-
-
-
-
-
Cheltenham, Storbritannien, GL53 7AN
- Upphängd
- Research Site
-
Inverness, Storbritannien, IV2 3UJ
- Upphängd
- Research Site
-
London, Storbritannien, SW17 0QT
- Rekrytering
- Research Site
-
London, Storbritannien, SW10 9NH
- Rekrytering
- Research Site
-
London, Storbritannien, SE1 9RT
- Indragen
- Research Site
-
Norwich, Storbritannien, NR4 7UY
- Rekrytering
- Research Site
-
Preston, Storbritannien, PR2 9HT
- Rekrytering
- Research Site
-
Truro, Storbritannien, TR1 3LJ
- Rekrytering
- Research Site
-
-
-
-
-
Changwon, Sydkorea, 51353
- Rekrytering
- Research Site
-
Incheon, Sydkorea, 21565
- Rekrytering
- Research Site
-
Seongnam-si, Sydkorea, 13496
- Rekrytering
- Research Site
-
Seoul, Sydkorea, 03080
- Rekrytering
- Research Site
-
Seoul, Sydkorea, 03722
- Rekrytering
- Research Site
-
Seoul, Sydkorea, 08308
- Har inte rekryterat ännu
- Research Site
-
Seoul, Sydkorea, 06973
- Rekrytering
- Research Site
-
Suwon, Sydkorea, 16247
- Rekrytering
- Research Site
-
Suwon, Sydkorea, 16499
- Rekrytering
- Research Site
-
-
-
-
-
Changhua, Taiwan, 500
- Har inte rekryterat ännu
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Rekrytering
- Research Site
-
New Taipei City, Taiwan, 220
- Rekrytering
- Research Site
-
Taichung, Taiwan, 40447
- Rekrytering
- Research Site
-
Taichung, Taiwan, 40705
- Rekrytering
- Research Site
-
Tainan, Taiwan, 704
- Rekrytering
- Research Site
-
Taipei, Taiwan, TAIWAN
- Rekrytering
- Research Site
-
Taipei, Taiwan, 10002
- Rekrytering
- Research Site
-
Taipei, Taiwan, 112
- Rekrytering
- Research Site
-
Taipei, Taiwan, 0116
- Rekrytering
- Research Site
-
Taoyuan, Taiwan, 333
- Rekrytering
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekrytering
- Research Site
-
Bangkok, Thailand, 10700
- Rekrytering
- Research Site
-
Hat Yai, Thailand, 90110
- Rekrytering
- Research Site
-
Muang, Thailand, 22000
- Rekrytering
- Research Site
-
Mueang, Thailand, 20000
- Rekrytering
- Research Site
-
Mueang, Thailand, 32000
- Rekrytering
- Research Site
-
-
-
-
-
Adapazarı, Turkiet (Türkiye), 54100
- Rekrytering
- Research Site
-
Ankara, Turkiet (Türkiye), 6200
- Rekrytering
- Research Site
-
Ankara, Turkiet (Türkiye), 06560
- Rekrytering
- Research Site
-
Antalya, Turkiet (Türkiye), 07070
- Rekrytering
- Research Site
-
Diyarbakır, Turkiet (Türkiye), 21280
- Rekrytering
- Research Site
-
Istanbul, Turkiet (Türkiye), 34030
- Rekrytering
- Research Site
-
Istanbul, Turkiet (Türkiye), 34890
- Rekrytering
- Research Site
-
-
-
-
-
Berlin, Tyskland, 10249
- Har inte rekryterat ännu
- Research Site
-
Bonn, Tyskland, 53113
- Rekrytering
- Research Site
-
Cologne, Tyskland, 50677
- Rekrytering
- Research Site
-
Düsseldorf, Tyskland, 40489
- Indragen
- Research Site
-
Essen, Tyskland, 45136
- Rekrytering
- Research Site
-
Freiburg im Breisgau, Tyskland, 79106
- Rekrytering
- Research Site
-
Gauting, Tyskland, 82131
- Rekrytering
- Research Site
-
Georgsmarienhütte, Tyskland, 49124
- Indragen
- Research Site
-
Gera, Tyskland, 07548
- Indragen
- Research Site
-
Gütersloh, Tyskland, 33332
- Indragen
- Research Site
-
Hamburg, Tyskland, 20251
- Rekrytering
- Research Site
-
Hamburg, Tyskland, 22087
- Rekrytering
- Research Site
-
Heidelberg, Tyskland, 69126
- Rekrytering
- Research Site
-
Kempten, Tyskland, 87439
- Upphängd
- Research Site
-
Kiel, Tyskland, 24116
- Har inte rekryterat ännu
- Research Site
-
Koblenz, Tyskland, 56068
- Upphängd
- Research Site
-
Ludwigsburg, Tyskland, 71640
- Indragen
- Research Site
-
München, Tyskland, 81925
- Rekrytering
- Research Site
-
Nuremberg, Tyskland, 90419
- Indragen
- Research Site
-
Potsdam, Tyskland, 14467
- Rekrytering
- Research Site
-
Ravensburg, Tyskland, 88212
- Rekrytering
- Research Site
-
-
-
-
-
Budapest, Ungern, 1121
- Rekrytering
- Research Site
-
Edelény, Ungern, 3780
- Har inte rekryterat ännu
- Research Site
-
Gyula, Ungern, 5700
- Upphängd
- Research Site
-
Gyöngyös, Ungern, 3200
- Indragen
- Research Site
-
Gyöngyös - Mátraháza, Ungern, 3200
- Rekrytering
- Research Site
-
Győr, Ungern, 9024
- Rekrytering
- Research Site
-
Kecskemét, Ungern, 6000
- Rekrytering
- Research Site
-
Salgótarján, Ungern, 3100
- Indragen
- Research Site
-
Szekszárd, Ungern, 7100
- Rekrytering
- Research Site
-
Szolnok, Ungern, 5000
- Indragen
- Research Site
-
Székesfehérvár, Ungern, 8000
- Indragen
- Research Site
-
Törökbálint, Ungern, 2045
- Rekrytering
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Rekrytering
- Research Site
-
Hanoi, Vietnam, 100000
- Rekrytering
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Rekrytering
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Indragen
- Research Site
-
Huế, Vietnam, 530000
- Indragen
- Research Site
-
Hà Nội, Vietnam, 100000
- Rekrytering
- Research Site
-
Vinh, Vietnam, 460000
- Indragen
- Research Site
-
Vĩnh Yên, Vietnam, 280000
- Rekrytering
- Research Site
-
-
-
-
-
Innsbruck, Österrike, 6020
- Rekrytering
- Research Site
-
Krems, Österrike, 3500
- Rekrytering
- Research Site
-
Linz, Österrike, 4020
- Rekrytering
- Research Site
-
Rankweil, Österrike, 6830
- Rekrytering
- Research Site
-
Vienna, Österrike, 1210
- Rekrytering
- Research Site
-
Vienna, Österrike, 1140
- Rekrytering
- Research Site
-
Wels, Österrike, 4600
- Indragen
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
Andra namn:
Rilvegostomig IV (intravenous)
Andra namn:
|
|
Experimentell: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
Andra namn:
|
|
Aktiv komparator: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Tidsram: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
Tidsram: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
Tidsram: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
Tidsram: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Tidsram: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Tidsram: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Tidsram: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Tidsram: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
Tidsram: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
Tidsram: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
Tidsram: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Tidsram: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D7632C00001
- 2023-505077-32-00 (Registeridentifierare: CTIS (EU))
- 2023 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .